Emricasan  
Item No. 22204

CAS Registry No.: 254750-02-2  
Formal Name: N-[2-(1,1-dimethylethyl)phenyl]-2-oxoglycyl-N-[(1S)-1-(carboxymethyl)-2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl]-L-alaninamide  
Synonyms: IDN-6556, PF-03491390  
MF: C_{26}H_{27}F_{4}N_{3}O_{7}  
FW: 569.5  
Purity: ≥98%  
UV/Vis.: λ_{max} 266 nm  
Supplied as: A crystalline solid  
Storage: -20°C  
Stability: ≥2 years  

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Emricasan is supplied as a crystalline solid. A stock solution may be made by dissolving the emricasan in the solvent of choice. Emricasan is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of emricasan in these solvents is approximately 30 mg/ml.

Description

Emricasan is a pan-caspase inhibitor.1-4 Ex vivo, emricasan (10 mg/kg) prevents cold ischemia-warm reperfusion-induced sinusoidal endothelial cell (SEC) apoptosis and inhibits caspase-3 activation in rat liver by 55 and 94%, respectively.1 In vivo, emricasan reduces alanine aminotransferase (ALT) levels (ED_{50} = <0.01-0.38 mg/kg) as well as apoptosis and caspase activity in a dose-dependent manner in the α-Fas mouse and D-Gln/LPS rat models of liver injury.2 Emricasan reduces caspase-3 and caspase-8 activity, serum ALT levels, hepatocyte apoptosis, and hepatic fibrogenesis in a mouse model of high-fat diet-induced non-alcoholic steatohepatitis (NASH).3 It also enhances islet engraftment and lowers post-transplant fasting glucose levels in a porcine islet autotransplant model.4

References